Simon Rothenfusser

Professor

Ludwig-Maximilians-Universität München
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Vaccines represent a major public health intervention against infectious diseases and potentially cancer. Surrogate markers of vaccine efficacy usually rely on neutralizing antibody titers afflicted by high interindividual variabilities. Automated multiplexed T cell assays currently allow to test the clinical relevance of T lymphocyte responses during vaccine rollout. We examined cellular and/or humoral immune responses in five independent cohorts of health care workers, young healthy individuals and patients with cancer (melanoma or lung cancer) receiving various immunizing formulations (non-replicating, viral/tumoral, mRNA/peptides/cellular/viral particles). Here we show that about 20% of vaccinees to non-replicating formulations fail to mount protective antibody and Th1/Tc1 responses while 9% receiving a live vaccine were hyperresponders. Vaccine outliers could at least in part be attributed to gut dysbiosis at baseline, evaluated by shotgun metagenomics-based machine learning or the TOPOSCORE. These findings highlight the requirement of diagnostic tools to identify intestinal dysbiosis, as well as microbiota-centered interventions to optimize the efficiency of mass vaccinations.

Year:

2025

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) requires lifelong glucocorticoid replacement to manage cortisol deficiency and excessive androgen production. Conventional circadian treatment (CT) tries to mimic natural cortisol rhythms, whereas reverse-circadian treatment (RC) prioritizes the suppression of adrenal androgen excess overnight through evening dosing. Limited data exist on the immunological impact of these regimens. A bi-centric study was conducted, including 41 pediatric and adolescent CAH patients. Peripheral blood samples were collected from patients on conventional treatment (n = 38) or RC (n = 16), with 11 RC patients switching to conventional treatment. Immune cell phenotypes, cytokine profiles, and natural killer (NK) cell cytotoxicity were assessed. Patients receiving RC showed lower percentages of CD4+CD25+ T cells (p = 0.0139). After the switch, patients with RC presented with a higher percentage of non-classical monocytes (p = 0.0255) and a lower percentage of Th17 cells (p = 0.0195). A lower expression of CD107 was observed with RC (p < 0.0001), as well as a higher percentage of NKp30 (p = 0.0189). Comparing patients after the switch from RC to HC, patients with RC presented with a lower NKG2D expression (p = 0.0420). Both conventional treatment and RC exhibited distinct immunological impacts, with CT showing modest advantages in normalizing immune phenotypes. These findings suggest that CT may offer immunological benefits for managing young patients with congenital adrenal hyperplasia.

Year:

2025

Yellow fever vaccination provides long-lasting protection and is a unique model for studying the immune response to an acute RNA virus infection in humans. To elucidate the early innate immune events preceding the rapid generation of protective immunity, we performed transcriptome analysis of human blood dendritic cell (DC) and monocyte subpopulations before and 3, 7, 14 and 28 days after vaccination. We detected temporary upregulation of IFN-stimulated genes (ISG) in all DC and monocyte subsets on day 3 and 7 after vaccination as well as cell type specific responses and temporal dynamics. Single cell RNA sequencing revealed rapid appearance of activated DC and monocyte clusters dominated by ISGs, inflammatory chemokines and genes involved in antigen processing and presentation. This was confirmed by flow cytometric analysis in a large cohort of vaccinees. We identified SIGLEC1/CD169 upregulation as a sensitive indicator of the transient IFN-induced activation state elicited in DCs and monocytes by YF17D vaccination correlating with early protective IgM antibody responses.

Year:

2024

Collaborators (20)

Giovanna Barba Spaeth

Directeur de Recherche, Associate professor

Institut Pasteur

FRANCE
View details

Guido Kroemer

-

FRANCE
View details

Valerio Iebba

Assistant Professor

University of Trieste

ITALY
View details

Didier Hocquet

Full Prof. - Hospital Practitioner

Hôpital Jean Minjoz

FRANCE
View details

olivier adotevi

INSERM UMR 1098 RIGHT

FRANCE
View details

Mathieu Chevalier

Assistant Professor

INSERM U976, Institut de Recherche Saint-Louis, Université de Paris

FRANCE
View details

Markus Maeurer

University of Mainz

GERMANY
View details

Julia Thorn-Seshold

Group Leader

Technische Universität Dresden

GERMANY
View details

laurence ZITVOGEL

Université Paris-Saclay

FRANCE
View details

Nicola Segata

Group Leader

University of Trento

ITALY
View details

Tobias Straub

Head

Ludwig-Maximilians-Universität München

GERMANY
View details

Sebastian Kobold

University Hospital

GERMANY
View details

I. Jolanda M. de Vries

Department head

Radboudumc

NETHERLANDS
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael White

Assistant Professor

-

UNITED STATES
View details

Lisa Derosa

Assistant Professor

Université Paris-Saclay

FRANCE
View details

Silvia Formenti

Cornell University

UNITED STATES
View details

Anne B. Krug

Ludwig-Maximilians-Universität München

GERMANY
View details

Sophie Caillat-Zucman

Professeur

Université Paris Diderot

FRANCE
View details

Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details